The Effect of the Reducing Sugars in the Synthesis of Visible-Light-Active Copper(I) Oxide Photocatalyst

In the present work, shape tailored Cu2O microparticles were synthesized by changing the nature of the reducing agent and studied subsequently. d-(+)-glucose, d-(+)-fructose, d-(+)xylose, d-(+)-galactose, and d-(+)-arabinose were chosen as reducing agents due to their different reducing abilities. The morpho-structural characteristics were studied by X-ray diffraction (XRD), scanning electron microscopy (SEM), and diffuse reflectance spectroscopy (DRS), while their photocatalytic activity was evaluated by methyl orange degradation under visible light (120 min). The results show that the number of carbon atoms in the sugars affect the morphology and particle size (from 250 nm to 1.2 µm), and differences in their degree of crystallinity and photocatalytic activity were also found. The highest activity was observed when glucose was used as the reducing agent

Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma

K

Hydrothermal Crystallization of Bismuth Oxychlorides (BiOCl) Using Different Shape Control Reagents

Bismuth oxychloride photocatalysts were obtained using solvothermal synthesis and different additives (CTAB—cetyltrimethylammonium bromide, CTAC—cetyltrimethylammonium chloride, PVP–polyvinylpyrrolidone, SDS–sodium dodecylsulphate, U—urea and TU—thiourea). The effect of the previously mentioned compounds was analyzed applying structural (primary crystallite size, crystal phase composition, etc.), morphological (particle geometry), optical (band gap energy) parameters, surface related properties (surface atoms’ oxidation states), and the resulted photocatalytic activity. A strong dependency was found between the surface tension of the synthesis solutions and the overall morpho-structural parameters. The main finding was that the characteristics of the semiconductors can be tuned by modifying the surface tension of the synthesis mixture. It was observed after the photocatalytic degradation, that the white semiconductor turned to grey. Furthermore, we attempted to explain the gray color of BiOCl catalysts after the photocatalytic decompositions by Raman and XPS studies

The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma

L

An outline of neotectonic structures and morphotectonics of the western and central Pannonian basin.

Neotectonic deformation in the western and central part of the Pannonian Basin was investigated by means of surface and subsurface structural analyses, and geomorphologic observations. The applied methodology includes the study of outcrops, industrial seismic profiles, digital elevation models, topographic maps, and borehole data. Observations suggest that most of the neotectonic structures in the Pannonian Basin are related to the inverse reactivation of earlier faults formed mainly during the Miocene syn- and post-rift phases. Typical structures are folds, blind reverse faults, and transpressional strike-slip faults, although normal or oblique-normal faults are also present. These structures significantly controlled the evolution of landforms and the drainage pattern by inducing surface upwarping and river deflections. Our analyses do not support the postulated tectonic origin of some landforms, particularly that of the radial valley system in the western Pannonian Basin. The most important neotectonic strike-slip faults are trending to east-northeast and have dextral to sinistral kinematics in the south-western and central-eastern part of the studied area, respectively. The suggested along-strike change of kinematics within the same shear zones is in agreement with the fan-shaped recent stress trajectories and with the present-day motion of crustal blocks derived from GPS data. © 2005 Elsevier B.V. All rights reserved

Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines

Uveal melanoma (UM) is the most common primary intraocular malignancy with very poor prognosis. Conventional chemotherapy only rarely prolongs the survival, therefore patients require novel treatment modalities. The discovery of specific receptors for hypothalamic hormones on cancer cells has led to the development of radiolabeled and cytotoxic hormone analogs. In the present study, our aim was to investigate the expression of mRNA for receptors of luteinizing hormone-releasing hormone type I (LH-RH-I) and LH-RH ligand in OCM-1 and OCM-3 human uveal melanoma cell lines. The presence and binding characteristics of LH-RH-I receptor protein was further studied by Western blot, immunocytochemistry and ligand competition assay. The expression of mRNA and protein for LH-RH-I receptors has been also studied using tumor samples originating from nude mice xenografted with OCM-1 or OCM-3 cells. The mRNA for LH-RH-I receptor has been detected in OCM-1 and OCM-3 cell lines and was found markedly higher in OCM-3 cells. The mRNA for LH-RH-I receptors was also observed in both UM xenograft models in vivo with higher levels in OCM-3. The presence of LH-RH-I receptor protein was found in both cell lines in vitro by immunocytochemistry and Western blot, and also in tumor tissue samples grown in nude mice by Western blot. Both human uveal melanoma models investigated showed specific high affinity receptors for LH-RH-I using ligand competition assay. The mRNA for LH-RH ligand has also been detected in OCM-1 and OCM-3 cell lines and cancer tissues. The demonstration of the expression of LH-RH-I receptors in OCM-1 and OCM-3 human UM cell lines suggests that they could serve as potential molecular target for therapy. Our findings support the development of new therapeutic approaches based on cytotoxic LH-RH analogs or modern powerful antagonistic analogs of LH-RH targeting LH-RH-I receptors in UM

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma

Uveal melanoma is the most common primary intraocular malignancy in adults, with a very high mortality rate due to frequent liver metastases. Consequently, the therapy of uveal melanoma remains a major clinical challenge and new treatment approaches are needed. For improving diagnosis and designing a rational and effective therapy, it is essential to elucidate molecular characteristics of this malignancy. The aim of this study therefore was to evaluate as a potential therapeutic target the expression of luteinizing hormone-releasing hormone (LHRH) receptor in human uveal melanoma. The expression of LHRH ligand and LHRH receptor transcript forms was studied in 39 human uveal melanoma specimens by RT-PCR using gene specific primers. The binding charachteristics of receptors for LHRH on 10 samples were determined by ligand competition assays. The presence of LHRH receptor protein was further evaluated by immunohistochemistry. The expression of mRNA for type I LHRH receptor was detected in 18 of 39 (46%) of tissue specimens. mRNA for LHRH-I ligand could be detected in 27 of 39 (69%) of the samples. Seven of 10 samples investigated showed high affinity LHRH-I receptors. The specific presence of full length LHRH receptor protein was further confirmed by immunohistochemistry. A high percentage of uveal melanomas express mRNA and protein for type-I LHRH receptors. Our results support the merit of further investigation of LHRH receptors in human ophthalmological tumors. Since diverse analogs of LHRH are in clinical trials or are already used for the treatment of various cancers, these analogs could be considered for the LHRH receptor-based treatment of uveal melanoma